Anzeige
Mehr »
Montag, 01.09.2025 - Börsentäglich über 12.000 News
Blockbuster-Potenzial und Übernahmefantasie: Hier entsteht das nächste Big Pharma-Ziel!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
269 Leser
Artikel bewerten:
(1)

Veeva Systems: Veeva Introduces New ePRO Application for Faster Access to Patient Data

Veeva ePRO simplifies the collection and exchange of patient-reported outcomes in digital clinical trials

BARCELONA, Spain, Oct. 18, 2022 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced the availability of Veeva ePRO, a key advancement in patient-centric digital trials. The application makes it easier for patients to complete assessments on a mobile device or web browser and enables real-time data access for sponsors and clinical research sites. As part of a connected platform for clinical trials, study teams can use ePRO to exchange high-quality data across the clinical ecosystem for improved transparency and collaboration.

Veeva Systems

According to research sites, the top challenges in patient retention include the time required to participate in a trial, repetitive information requests, and time spent entering data.1 Veeva ePRO improves the patient experience by providing a modern, user-friendly application for completing Patient-Reported Outcomes (PRO).

The application also helps streamline trial activities for sponsors and research sites. Sponsors can configure studies using survey and instrument libraries and push ePRO and schedule definitions to research sites. Research sites can then easily assign activities, automatically receive updates, and track patient progress without needing other systems or applications.

"Veeva ePRO is built to meet the needs of patients, sites, and sponsors, and is connected for end-to-end execution," said Tim Davis, vice president of strategy, MyVeeva for Patients at Veeva. "We are committed to partnering with customers to deliver modern digital applications that help the life sciences industry advance to patient-centric digital trials."

Veeva ePRO is part of Veeva Vault Clinical Suite, the industry's first cloud platform that unifies clinical data management and operations. Vault Clinical Suite includes Vault EDC, Veeva RTSM, Veeva ePRO, Veeva CDB, Vault eTMF, Vault CTMS, Veeva Site Connect, Vault Payments, Vault Study Start-up, and Vault Study Training. Learn more about Veeva ePRO at veeva.com/eu/ePRO.

Additional Information

Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems Follow @veeva_eu on Twitter: twitter.com/veeva_eu

About Veeva Systems

Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu.

Veeva Forward-looking Statements

This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services, including certain of our new solutions and applications that are still under development or not generally available. These statements are based on our current expectations. Actual results, availability, and any future events relating to these products and services could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended July 31, 2022, which you can find here (a summary of risks which may impact our business can be found on pages 39 and 40), and in our subsequent SEC filings, which you can access at sec.gov.

1 SCRS Research Report, Impact Assessment of eClinical Technologies and Industry Initiatives on Sites, 2019

Contact:



Jeremy Whittaker

Deivis Mercado

Veeva Systems

Veeva Systems

+49-695-095-5486

925-226-8821

jeremy.whittaker@veeva.com

deivis.mercado@veeva.com

Logo - https://mma.prnewswire.com/media/1488285/Veeva_Systems_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/veeva-introduces-new-epro-application-for-faster-access-to-patient-data-301651799.html

© 2022 PR Newswire
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.